Trial Profile
An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With sJIA Who Participated in Studies MRA011JP or MRA316JP [EXTENSION OF 700009800]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 May 2014
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 01 May 2014 Results published in The Journal of Rheumatology.
- 28 Mar 2008 Status change
- 22 Mar 2008 Status change from in progress to completed